Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DARENASDAQ:LGVNNASDAQ:VSTMNASDAQ:XLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAREDare Bioscience$2.56-9.2%$2.96$2.56▼$5.76$24.96M1.237,096 shs98,324 shsLGVNLongeveron$1.15-4.2%$1.39$1.14▼$6.40$17.91M0.221.40 million shs135,401 shsVSTMVerastem$4.62-6.3%$6.70$2.10▼$9.10$270.90M0.851.19 million shs2.91 million shsXLOXilio Therapeutics$0.67-2.7%$0.78$0.62▼$1.70$35.65M-0.011.42 million shs750,299 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAREDare Bioscience-9.22%-13.80%-11.72%-11.11%-50.90%LGVNLongeveron-4.17%-10.85%-14.81%-35.39%-47.73%VSTMVerastem-6.29%-18.09%-44.40%-29.68%+46.20%XLOXilio Therapeutics-2.69%-2.33%-24.19%-11.84%-26.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDAREDare Bioscience1.1794 of 5 stars3.33.00.00.00.60.00.0LGVNLongeveron3.1636 of 5 stars3.65.00.00.00.61.71.3VSTMVerastem2.1356 of 5 stars3.52.00.00.00.72.50.6XLOXilio Therapeutics3.6355 of 5 stars3.55.00.00.03.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAREDare Bioscience 2.50Moderate Buy$12.00368.75% UpsideLGVNLongeveron 3.25Buy$8.67653.62% UpsideVSTMVerastem 3.00Buy$13.63194.91% UpsideXLOXilio Therapeutics 3.00Buy$4.00497.01% UpsideCurrent Analyst Ratings BreakdownLatest DARE, VSTM, XLO, and LGVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $14.004/10/2025VSTMVerastemJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/9/2025VSTMVerastemMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.004/1/2025DAREDare BioscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/24/2025VSTMVerastemGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $14.003/24/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAREDare Bioscience$10K2,265.60N/AN/A($0.69) per share-3.71LGVNLongeveron$2.39M7.18N/AN/A$1.47 per share0.78VSTMVerastem$10K25,386.90N/AN/A($0.65) per share-7.11XLOXilio Therapeutics$6.34M5.47N/AN/A$0.40 per share1.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAREDare Bioscience-$4.05M-$0.17N/AN/AN/A-191.65%N/A-8.14%8/11/2025 (Estimated)LGVNLongeveron-$15.97M-$6.28N/AN/AN/A-760.72%-85.07%-70.74%8/13/2025 (Estimated)VSTMVerastem-$130.64M-$3.20N/AN/AN/AN/A-2,003.62%-127.97%8/6/2025 (Estimated)XLOXilio Therapeutics-$58.24M-$0.84N/AN/AN/A-585.54%-262.69%-64.01%8/14/2025 (Estimated)Latest DARE, VSTM, XLO, and LGVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025DAREDare Bioscience-$0.63-$0.50+$0.13-$0.50$0.60 million$0.03 million5/13/2025Q1 2025VSTMVerastem-$0.72-$0.96-$0.24-$0.96$0.10 millionN/A5/13/2025Q1 2025XLOXilio Therapeutics$0.10-$0.18-$0.28-$0.18$42.00 million$2.93 million3/31/2025Q4 2024DAREDare Bioscience-$0.66-$0.64+$0.02-$0.64$1.00 million($0.06) millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDAREDare BioscienceN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/AXLOXilio TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAREDare BioscienceN/A0.560.56LGVNLongeveronN/A5.615.61VSTMVerastem2.773.503.50XLOXilio TherapeuticsN/A1.961.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAREDare Bioscience6.70%LGVNLongeveron10.01%VSTMVerastem88.37%XLOXilio Therapeutics54.29%Insider OwnershipCompanyInsider OwnershipDAREDare Bioscience4.00%LGVNLongeveron11.20%VSTMVerastem2.10%XLOXilio Therapeutics6.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAREDare Bioscience308.85 million8.50 millionNot OptionableLGVNLongeveron2014.93 million13.26 millionNot OptionableVSTMVerastem5054.95 million53.80 millionOptionableXLOXilio Therapeutics7051.78 million48.52 millionNot OptionableDARE, VSTM, XLO, and LGVN HeadlinesRecent News About These CompaniesJames Samuel Shannon Acquires 25,000 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) StockJune 19, 2025 | insidertrades.comXilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest UpdateJune 16, 2025 | americanbankingnews.comXilio Therapeutics expands board, elects new directorJune 13, 2025 | investing.comXilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of DirectorsJune 10, 2025 | quiverquant.comXilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of DirectorsJune 10, 2025 | globenewswire.comXilio Therapeutics Announces Closing of $50.0 Million Public OfferingJune 5, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2025 | globenewswire.comXilio Therapeutics Announces Pricing of $50.0 Million Public OfferingJune 2, 2025 | globenewswire.comXilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite ...June 2, 2025 | stockhouse.comXilio Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Pre-Funded Warrants and Series A, B, and C WarrantsJune 2, 2025 | quiverquant.comXilio Therapeutics Announces Proposed Public OfferingJune 2, 2025 | globenewswire.comXilio Therapeutics, Inc. (XLO) Reports 26% Response in Colon Cancer Drug TrialMay 31, 2025 | insidermonkey.comXilio Therapeutics Reports Preliminary 26% Objective Response Rate in Phase 2 Trial of Vilastobart Combined with Atezolizumab for Metastatic MSS Colorectal CancerMay 31, 2025 | quiverquant.comXilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal CancerMay 31, 2025 | globenewswire.comXilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial ResultsMay 8, 2025 | finanznachrichten.deXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial ResultsMay 8, 2025 | finance.yahoo.comXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comXilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual MeetingApril 23, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDARE, VSTM, XLO, and LGVN Company DescriptionsDare Bioscience NASDAQ:DARE$2.56 -0.26 (-9.22%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$2.87 +0.31 (+12.11%) As of 06/23/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.Longeveron NASDAQ:LGVN$1.15 -0.05 (-4.17%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$1.18 +0.03 (+2.61%) As of 06/23/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.Verastem NASDAQ:VSTM$4.62 -0.31 (-6.29%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$4.65 +0.03 (+0.74%) As of 06/23/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.Xilio Therapeutics NASDAQ:XLO$0.67 -0.02 (-2.69%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$0.68 +0.01 (+0.75%) As of 06/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
